Cabozantinib Approved in Europe for Second-Line HCC

November 15, 2018 – Combining lenvatinib with PD-1 inhibitors had promising efficacy in patients with advanced intrahepatic cholangiocarcinoma (ICC), according to preliminary data from a single-center study reported at the 2018 Gastrointestinal Cancers Symposium. The European Commission (EC) has approved cabozantinib for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, according to … (leggi tutto)